Provided by Tiger Trade Technology Pte. Ltd.

BioAge Labs Inc.

6.61
-0.2000-2.94%
Post-market: 6.610.00000.00%16:15 EDT
Volume:869.63K
Turnover:5.78M
Market Cap:303.38M
PE:-2.79
High:6.92
Open:6.92
Low:6.47
Close:6.81
52wk High:25.96
52wk Low:5.04
Shares:45.90M
Float Shares:37.58M
Volume Ratio:1.36
T/O Rate:2.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3710
EPS(LYR):-2.2432
ROE:-28.21%
ROA:-18.47%
PB:0.81
PE(LYR):-2.95

Loading ...

BioAge Labs Doses First Patient in Phase 2 QUELL-DME Trial of Oral NLRP3 Inhibitor BGE-102

Reuters
·
37 mins ago

BioAge Labs to Present at Upcoming Investor Conferences

GlobeNewswire
·
Sep 26

Analysts Offer Insights on NA Companies: Fair Isaac (FICO), Freeport-McMoRan (FCX) and BioAge Labs, Inc. (BIOA)

TIPRANKS
·
Sep 14

BioAge Labs Price Target Maintained with a $25.00/Share by Roth Capital

Dow Jones
·
Sep 10

BioAge Labs Price Target Maintained with a $40.00/Share by BTIG

Dow Jones
·
Sep 08

BioAge Labs doses first patient in QUELL-DME study

TIPRANKS
·
Sep 08

Bioage Labs - Topline Results from Quell-Dme Trial Expected in Second Half of 2027

THOMSON REUTERS
·
Sep 08

Bioage Labs Announces First Participant Dosed in Quell-Dme, a Phase 2 Trial of Bge-102, a Novel Oral Nlrp3 Inhibitor, in Diabetic Macular Edema

THOMSON REUTERS
·
Sep 08

BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema

GlobeNewswire
·
Sep 08

BioAge Labs to Present at Citi Biopharma Back to School Conference Fireside Chat

Reuters
·
Sep 02

BioAge Labs to Present at Upcoming Investor Conferences

GlobeNewswire
·
Sep 02

BioAge Labs price target lowered to $20 from $23 at Morgan Stanley

TIPRANKS
·
Aug 07

Analysts’ Opinions Are Mixed on These NA Stocks: BioAge Labs, Inc. (BIOA) and Fiserv (FISV)

TIPRANKS
·
Aug 07

BioAge Labs Price Target Maintained with a $40.00/Share by BTIG

Dow Jones
·
Aug 06

BioAge Labs, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Bioage Labs Q2 EPS $(0.58) Beats $(0.60) Estimate, Sales $2.451M Beat $1.920M Estimate

Benzinga Earnings
·
Aug 06

BioAge Q2 FY26 Net Loss Widens to $26.1 Million; R&D Expenses Rise to $24.37 Million

Reuters
·
Aug 06

Bioage Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates

THOMSON REUTERS
·
Aug 06

BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates

GlobeNewswire
·
Aug 06

Analysts Offer Insights on NA Companies: Central Bancompany (CBC) and BioAge Labs, Inc. (BIOA)

TIPRANKS
·
Aug 03